Tevogen Bio Holdings Inc
TVGNW0.049USD
-0.000-0.81%
Market hours （ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Tevogen Bio Holdings Inc Company
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.
Company Info
Company codeTVGNW
Company nameTevogen Bio Holdings Inc
IPO dateNov 04, 2021
Founded at2024
CEODr. Ryan Saadi, M.D.
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address15 Independence Boulevard, Suite 410
CityWARREN
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code07059
Phone16468078832
Websitehttps://tevogen.com/
Company codeTVGNW
IPO dateNov 04, 2021
Founded at2024
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Neal Flomenberg, M.D.
Dr. Neal Flomenberg, M.D.
Chief Scientific Officer and Global R&D Lead
Chief Scientific Officer and Global R&D Lead
--
--
Mr. Jeffrey Feike
Mr. Jeffrey Feike
Independent Director Nominee
Independent Director Nominee
--
--
Ms. Susan M. Podlogar
Ms. Susan M. Podlogar
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Victor Sordillo
Mr. Victor Sordillo
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Kirti Desai
Mr. Kirti Desai
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Ryan Saadi, M.D.
Dr. Ryan Saadi, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Curtis Patton
Dr. Curtis Patton
Independent Director Nominee
Independent Director Nominee
--
--
Dr. Keow Lin (Lindee) Goh
Dr. Keow Lin (Lindee) Goh
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Surendra (Suren) Ajjarapu
Mr. Surendra (Suren) Ajjarapu
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Sadiq Khan
Mr. Sadiq Khan
Chief Commercial Officer
Chief Commercial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Neal Flomenberg, M.D.
Dr. Neal Flomenberg, M.D.
Chief Scientific Officer and Global R&D Lead
Chief Scientific Officer and Global R&D Lead
--
--
Mr. Jeffrey Feike
Mr. Jeffrey Feike
Independent Director Nominee
Independent Director Nominee
--
--
Ms. Susan M. Podlogar
Ms. Susan M. Podlogar
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Victor Sordillo
Mr. Victor Sordillo
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Kirti Desai
Mr. Kirti Desai
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Ryan Saadi, M.D.
Dr. Ryan Saadi, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Sun, Feb 23
Update time: Sun, Feb 23
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Other
100.00%
Shareholder Statistics
Shareholder
Proportion
Other
100.00%
Type
Shareholder
Proportion
Other
100.00%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
65
14.15M
0.00%
-3.01M
2024Q4
69
14.15M
0.00%
-3.24M
2024Q3
73
15.05M
0.00%
-2.82M
2024Q2
74
15.32M
0.00%
-2.48M
2024Q1
73
15.60M
0.00%
-2.66M
2023Q4
71
16.67M
0.00%
-144.22K
2023Q3
71
15.71M
0.00%
-753.59K
2023Q2
71
15.36M
0.00%
-1.08M
2023Q1
71
15.53M
0.00%
-387.68K
2022Q4
61
15.25M
0.00%
+1.25M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Highbridge Capital Management, LLC
2.57M
0%
+500.93K
+24.23%
Dec 31, 2024
Parallax Volatility Advisers, L.P.
1.68M
0%
-479.65K
-22.17%
Dec 31, 2024
Fourworld Capital Management LLC
1.45M
0%
--
--
Dec 31, 2024
Corbin Capital Partners, L.P.
1.16M
0%
--
--
Dec 31, 2024
Calamos Advisors LLC
1.00M
0%
--
--
Dec 31, 2024
Greenland Capital Management LP
703.03K
0%
--
--
Dec 31, 2024
Polar Asset Management Partners Inc.
700.00K
0%
-17.31K
-2.41%
Dec 31, 2024
MMCAP Asset Management
650.00K
0%
--
--
Dec 31, 2024
Linden Advisors L.P.
650.00K
0%
--
--
Dec 31, 2024
Atalaya Capital Management LP
300.00K
0%
--
--
Jun 30, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data